Antonia Valenzuela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonia Valenzuela has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Lorinda Chung
Stanford University School of Medicine, Stanford, California, USA
3 shared publications- Lorinda Chung
Division of Immunology and Rheumatology, Department of Medicine Stanford University Stanford California
3 shared publications - Arturo Borzutzky
Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
2 shared publications - John D. Pauling
Department of Rheumatology, North Bristol NHS Trust, Bristol, UK
2 shared publications Kim Fligelstone
Patient Research Partner, London, UK
2 shared publications- Latika Gupta
Department of Rheumatology Royal Wolverhampton Hospitals NHS Trust Wolverhampton UK
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey
Objectives: To evaluate contemporary global treatment of diffuse cutaneous systemic sclerosis (dcSSc) skin by SSc specialists. Methods: An anonymous survey was distributed via the Scleroderma Clinical Trials Consortium, European Scleroderma Trials and Research Group (EUSTAR), and Collaborative National Quality and Efficacy Registry (CONQUER) distribution lists between June–September 2025. The survey comprised four sections: Demographics, Treatment of dcSSc Skin, Impact of Recent Guidelines, and Clinical Trials. Results: Responses included 103 physicians (93 completed): 43% North America, 31% Europe, 15% South America, and 12% elsewhere. The majority practice within an SSc centre (80%) and participate in clinical trials (84%). Mycophenolate mofetil (MMF) was preferred first-line treatment (71%) for dcSSc without ILD, rising to 92% for dcSSc with mild/non-progressive ILD. For active skin involvement despite MMF, trial referral was preferred as next step irrespective of ILD (59% without ILD and 58% with ILD). Treatment preferences have evolved, with 40% increasing MMF use and 47% decreasing methotrexate use, over previous 2–3 years. Biologic use has increased, with 56% and 37% reporting increasing rituximab and tocilizumab use, respectively. For dcSSc without ILD, 85% have prescribed rituximab, and 65% have prescribed tocilizumab. Biologic availability has impacted trial enrolment (73% agreement). Treatment decision-making for dcSSc skin involvement has been materially influenced by recent BSR and/or EULAR guidelines (43% agreement). Conclusion: MMF is preferred first-line for dcSSc. In absence of compelling scientific justification for combination or step-up immunomodulatory approaches, trial referral is currently the preferred next treatment option. Biologic use is increasing which impacts trial enrolment.
- 21 July 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
Open AccessTreating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey
Objectives: To evaluate contemporary global treatment of diffuse cutaneous systemic sclerosis (dcSSc) skin by SSc specialists. Methods: An anonymous survey was distributed via the Scleroderma Clinical Trials Consortium, European Scleroderma Trials and Research Group (EUSTAR), and Collaborative National Quality and Efficacy Registry (CONQUER) distribution lists between June–September 2025. The survey comprised four sections: Demographics, Treatment of dcSSc Skin, Impact of Recent Guidelines, and Clinical Trials. Results: Responses included 103 physicians (93 completed): 43% North America, 31% Europe, 15% South America, and 12% elsewhere. The majority practice within an SSc centre (80%) and participate in clinical trials (84%). Mycophenolate mofetil (MMF) was preferred first-line treatment (71%) for dcSSc without ILD, rising to 92% for dcSSc with mild/non-progressive ILD. For active skin involvement despite MMF, trial referral was preferred as next step irrespective of ILD (59% without ILD and 58% with ILD). Treatment preferences have evolved, with 40% increasing MMF use and 47% decreasing methotrexate use, over previous 2–3 years. Biologic use has increased, with 56% and 37% reporting increasing rituximab and tocilizumab use, respectively. For dcSSc without ILD, 85% have prescribed rituximab, and 65% have prescribed tocilizumab. Biologic availability has impacted trial enrolment (73% agreement). Treatment decision-making for dcSSc skin involvement has been materially influenced by recent BSR and/or EULAR guidelines (43% agreement). Conclusion: MMF is preferred first-line for dcSSc. In absence of compelling scientific justification for combination or step-up immunomodulatory approaches, trial referral is currently the preferred next treatment option. Biologic use is increasing which impacts trial enrolment.
- Open Access
- 26 May 2026
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 11 (1) , e000009
Scleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis
The Scleroderma Clinical Trials Consortium (SCTC) is committed to advancing the understanding and treatment of systemic sclerosis (SSc). This review focuses on the development and validation of various outcome instruments by the SCTC, which are crucial for evaluating the effectiveness of interventions in clinical trials and observational studies. Key instruments discussed include the Assessment of Systemic Sclerosis-Associated RAynaud’s Phenomenon Questionnaire, the SCTC Radiologic Scoring System for calcinosis, the Mawdsley Questionnaire for calcinosis, the University of California Los Angeles SCTC Gastrointestinal Tract Instrument (GIT) 2.0, the SCTC Activity Index and the SCTC Damage Index. Additionally, the SCTC and World Scleroderma Foundation (WSF) Skin Scoring Certification is highlighted as an important resource for researchers. Each instrument’s purpose, description and validation process are examined, underscoring their pivotal role in advancing SSc research and improving patient outcomes.
- 26 May 2026
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 11 (1) , e000009
Open AccessScleroderma Clinical Trials Consortium (SCTC) outcome instruments for evaluation of systemic sclerosis
The Scleroderma Clinical Trials Consortium (SCTC) is committed to advancing the understanding and treatment of systemic sclerosis (SSc). This review focuses on the development and validation of various outcome instruments by the SCTC, which are crucial for evaluating the effectiveness of interventions in clinical trials and observational studies. Key instruments discussed include the Assessment of Systemic Sclerosis-Associated RAynaud’s Phenomenon Questionnaire, the SCTC Radiologic Scoring System for calcinosis, the Mawdsley Questionnaire for calcinosis, the University of California Los Angeles SCTC Gastrointestinal Tract Instrument (GIT) 2.0, the SCTC Activity Index and the SCTC Damage Index. Additionally, the SCTC and World Scleroderma Foundation (WSF) Skin Scoring Certification is highlighted as an important resource for researchers. Each instrument’s purpose, description and validation process are examined, underscoring their pivotal role in advancing SSc research and improving patient outcomes.
- 8 December 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (3) , 352-361
International Investigation of the Gut‐Lung Axis in Systemic Sclerosis–Interstitial Lung Disease
Objective: Mounting evidence supports an association between the intestinal microbiota and diverse pulmonary pathologies (ie, gut‐lung axis). Although intestinal dysbiosis is a feature of systemic sclerosis (SSc), no prior studies have investigated the relationship between intestinal microbiota and SSc‐associated interstitial lung disease (ILD) in a multinational cohort. This study aimed to characterize the intestinal microbiota of SSc‐ILD and determine whether specific bacterial species and functional pathways are associated with ILD severity. Methods: Patients with SSc with and without ILD from seven SSc Centers across five continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000 to characterize microbial composition at the species level. Quantitative image analysis of high‐resolution computed tomography scans of the chest was used to measure radiologic extent of ILD (QILD). Multivariate sparse partial least squares analyses were employed to identify a species signature of ILD and to determine whether specific species and functional pathways are associated with QILD. Results: Among 285 participants (mean disease duration of 9.8 years), 62.5% had ILD. In a multivariate analysis of all participants, patients with ILD had a unique microbial signature compared to those without ILD characterized by increased abundance of candidate pathobiont species. In a subgroup of participants with SSc‐ILD (n = 103), specific bacterial species and functional pathways were associated with QILD. Conclusion: This multicenter study demonstrates that distinct intestinal bacterial species are linked to the presence and radiologic extent of ILD in SSc. These species and/or their metabolic products may influence ILD pathogenesis and represent novel treatment targets.
- 8 December 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (3) , 352-361
International Investigation of the Gut‐Lung Axis in Systemic Sclerosis–Interstitial Lung Disease
Objective: Mounting evidence supports an association between the intestinal microbiota and diverse pulmonary pathologies (ie, gut‐lung axis). Although intestinal dysbiosis is a feature of systemic sclerosis (SSc), no prior studies have investigated the relationship between intestinal microbiota and SSc‐associated interstitial lung disease (ILD) in a multinational cohort. This study aimed to characterize the intestinal microbiota of SSc‐ILD and determine whether specific bacterial species and functional pathways are associated with ILD severity. Methods: Patients with SSc with and without ILD from seven SSc Centers across five continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000 to characterize microbial composition at the species level. Quantitative image analysis of high‐resolution computed tomography scans of the chest was used to measure radiologic extent of ILD (QILD). Multivariate sparse partial least squares analyses were employed to identify a species signature of ILD and to determine whether specific species and functional pathways are associated with QILD. Results: Among 285 participants (mean disease duration of 9.8 years), 62.5% had ILD. In a multivariate analysis of all participants, patients with ILD had a unique microbial signature compared to those without ILD characterized by increased abundance of candidate pathobiont species. In a subgroup of participants with SSc‐ILD (n = 103), specific bacterial species and functional pathways were associated with QILD. Conclusion: This multicenter study demonstrates that distinct intestinal bacterial species are linked to the presence and radiologic extent of ILD in SSc. These species and/or their metabolic products may influence ILD pathogenesis and represent novel treatment targets.
- 6 September 2025
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 51 (4) , 655-673
Calcinosis in Adult and Juvenile Dermatomyositis
- 6 September 2025
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 51 (4) , 655-673
Calcinosis in Adult and Juvenile Dermatomyositis
- Open Access
- 2 April 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (4) , e70029
Osteoclastogenesis in Patients With Systemic Sclerosis With and Without Calcinosis Cutis
Objective: We aimed to assess whether the presence of radiographically confirmed calcinosis of the hands in patients with systemic sclerosis (SSc) is associated with increased osteoclastogenesis.Methods: We recruited 20 patients with SSc (10 with calcinosis and 10 without calcinosis) and 10 age‐ and gender‐matched healthy controls. Hand radiographs were scored using the validated Scleroderma Clinical Trials Consortium (SCTC) radiographic severity score for calcinosis. To evaluate osteoclastogenesis, peripheral blood mononuclear cells (PBMCs) were cultured with RANKL and macrophage colony‐stimulating factor; osteoclasts were identified using tartrate‐resistant acid phosphatase staining. Measures of bone resorption (RANKL, osteoprotegerin [OPG]) and ischemia or endothelial function (vascular endothelial growth factor, angiopoietin‐1, and angiopoietin‐2 [Ang‐2]) were also evaluated.Results: Patients with SSc were all women and Hispanic, and the majority (n = 12, 60%) had limited SSc skin type. Mean ± SD age was 55.2 ± 14.8 years; mean ± SD disease duration was 9.5 ± 6.5 years from first non‐Raynaud phenomenon symptom. Patients with SSc with calcinosis had more digital ischemia than patients without calcinosis. Median SCTC score in patients with SSc with calcinosis was 11.1 (range 0.7–286). After 9 days in culture, PBMCs from patients with calcinosis originated a significantly higher number of osteoclasts (33.0 ± 20.3 cells/well) than patients without calcinosis (15.3 ± 6.9 cells/well) and healthy individuals (11.2 ± 2.6 cells/well) (P = 0.001). The severity of calcinosis was not correlated with the number of osteoclasts per well (r = 0.27, P = 0.5); however, it was correlated with RANKL (r = 0.82, P = 0.004), RANKL/OPG ratio (r = 0.86, P = 0.002), and Ang‐2 levels (r = 0.86, P = 0.002).Conclusion: Calcinosis in patients with SSc is associated with an increased propensity of peripheral blood cells to form osteoclasts. Targeted inhibition of osteoclastogenesis may provide a specific therapeutic option for patients with SSc‐associated calcinosis.
- 2 April 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (4) , e70029
Open AccessOsteoclastogenesis in Patients With Systemic Sclerosis With and Without Calcinosis Cutis
Objective: We aimed to assess whether the presence of radiographically confirmed calcinosis of the hands in patients with systemic sclerosis (SSc) is associated with increased osteoclastogenesis.Methods: We recruited 20 patients with SSc (10 with calcinosis and 10 without calcinosis) and 10 age‐ and gender‐matched healthy controls. Hand radiographs were scored using the validated Scleroderma Clinical Trials Consortium (SCTC) radiographic severity score for calcinosis. To evaluate osteoclastogenesis, peripheral blood mononuclear cells (PBMCs) were cultured with RANKL and macrophage colony‐stimulating factor; osteoclasts were identified using tartrate‐resistant acid phosphatase staining. Measures of bone resorption (RANKL, osteoprotegerin [OPG]) and ischemia or endothelial function (vascular endothelial growth factor, angiopoietin‐1, and angiopoietin‐2 [Ang‐2]) were also evaluated.Results: Patients with SSc were all women and Hispanic, and the majority (n = 12, 60%) had limited SSc skin type. Mean ± SD age was 55.2 ± 14.8 years; mean ± SD disease duration was 9.5 ± 6.5 years from first non‐Raynaud phenomenon symptom. Patients with SSc with calcinosis had more digital ischemia than patients without calcinosis. Median SCTC score in patients with SSc with calcinosis was 11.1 (range 0.7–286). After 9 days in culture, PBMCs from patients with calcinosis originated a significantly higher number of osteoclasts (33.0 ± 20.3 cells/well) than patients without calcinosis (15.3 ± 6.9 cells/well) and healthy individuals (11.2 ± 2.6 cells/well) (P = 0.001). The severity of calcinosis was not correlated with the number of osteoclasts per well (r = 0.27, P = 0.5); however, it was correlated with RANKL (r = 0.82, P = 0.004), RANKL/OPG ratio (r = 0.86, P = 0.002), and Ang‐2 levels (r = 0.86, P = 0.002).Conclusion: Calcinosis in patients with SSc is associated with an increased propensity of peripheral blood cells to form osteoclasts. Targeted inhibition of osteoclastogenesis may provide a specific therapeutic option for patients with SSc‐associated calcinosis.
- 16 September 2024
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 50 (4) , 661-681
Vascular, Soft Tissue, and Musculoskeletal Imaging in Systemic Sclerosis
- 16 September 2024
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 50 (4) , 661-681
Vascular, Soft Tissue, and Musculoskeletal Imaging in Systemic Sclerosis
- Open Access
- 19 June 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (12) , 3203-3204
The power of quantitative algorithms in nailfold videocapillaroscopy
Antonia Valenzuela, MD, MS, Sara Concha, MD, Cristiane Kayser, MD, PhD; The Power of Quantitative Algorithms in Nailfold Videocapillaroscopy, Rheumatology,
- 19 June 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (12) , 3203-3204
Open AccessThe power of quantitative algorithms in nailfold videocapillaroscopy
Antonia Valenzuela, MD, MS, Sara Concha, MD, Cristiane Kayser, MD, PhD; The Power of Quantitative Algorithms in Nailfold Videocapillaroscopy, Rheumatology,
- 24 April 2024
- Published by Springer Nature
- p. 527-542
Calcinosis
- Open Access
- 13 April 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (7) , 2650-2653
Acute calcific tendinitis of the longus colli: A case report
- 13 April 2024
- Published by Elsevier in Radiology Case Reports
- Vol. 19 (7) , 2650-2653
Open AccessAcute calcific tendinitis of the longus colli: A case report
- Open Access
- 28 March 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (11) , e22
Correspondence on ‘Current myositis clinical trials and tribulations’ by Saygin et al
- 28 March 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (11) , e22
Open AccessCorrespondence on ‘Current myositis clinical trials and tribulations’ by Saygin et al